baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

RAPT Therapeutics/ US75382E1091 /

9/10/2024 9:59:55 PM	Chg. -0.03	Volume	Bid-	Ask-	High	Low
2.00USD	-1.24%	4,781 Turnover: 9,485.26	-Bid Size: -	-Ask Size: -	2.09	1.92

GlobeNewswire 8/8 RAPT Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire 5/9 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeut...

GlobeNewswire 5/9 RAPT Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire 4/9 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with...

GlobeNewswire 3/12 RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT S...

GlobeNewswire 3/7 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 3/7 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 3/5 RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Associatio...

GlobeNewswire 2/28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 2/21 RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claim...

GlobeNewswire 2/21 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 2/20 Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC

GlobeNewswire 2/20 RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

GlobeNewswire 2/13 RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vic...

GlobeNewswire 1/31 RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Confere...

GlobeNewswire 1/2 RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 11/27/2023 RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Tre...

GlobeNewswire 11/13/2023 RAPT Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire 11/3/2023 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free S...

GlobeNewswire 11/1/2023 RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

GlobeNewswire 10/18/2023 RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SIT...

GlobeNewswire 8/30/2023 RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

GlobeNewswire 3/28/2022 RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Mod...

GlobeNewswire 3/10/2022 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

GlobeNewswire 2/15/2022 Portage Biotech Announces New Appointments to its Management Team and Board of Directors

RAPT Therapeutics/ US75382E1091 /

If you wish to receive reply to your feedback, please provide your email address.